Article Text

Download PDFPDF
Multimodal Management of Locally Advanced Neuroendocrine Cervical Carcinoma: A Single Institution Experience
  1. Pauline Castelnau-Marchand, MD*,
  2. Patricia Pautier, MD,
  3. Catherine Genestie, MD,
  4. Alexandra Leary, MD, PhD,
  5. Enrica Bentivegna, MD§,
  6. Sébastien Gouy, MD, PhD§,
  7. Jean-Yves Scoazec, MD, PhD,
  8. Philippe Morice, MD, PhD§,
  9. Christine Haie-Meder, MD* and
  10. Cyrus Chargari, MD, PhD*,,#
  1. * Brachytherapy Unit, Radiation Oncology,
  2. Departments of Medical Oncology,
  3. Pathology, and
  4. § Surgery, Gustave Roussy, Villejuif;
  5. Université Paris Sud XI, Faculté de Médecine de Bicêtre, Le Kremlin-Bicêtre;
  6. French Military Health Services Academy, Ecole du Val-de-Grâce, Paris; and
  7. # Institut de Recherche Biomédicale des Armées, Brétigny sur Orge, France.
  1. Address correspondence and reprint requests to Pauline Castelnau-Marchand, MD, Gustave Roussy Cancer Campus, 114, rue Edouard Vaillant, 94805 Villejuif Cedex, France. E-mail: Pauline.castelnau.marchand{at}


Objective The aim of this study was to report our institutional experience of a multimodal approach for treatment of locally advanced high-grade neuroendocrine cervical cancer.

Methods and Materials Patients with primary locally advanced neuroendocrine cervical cancer diagnosed between 2001 and 2014 were included. The scheduled treatment sequence was as follows: pelvic +/− para-aortic radiotherapy (according to tumor stage), associated with chemotherapy based on platine-derivate and etoposide regimen, followed with a brachytherapy boost, then completion surgery if there was no progression +/− consolidation etoposide chemotherapy (for a total of 5–6 cycles). Disease-free survival (DFS) and overall survival (OS) were reported and prognostic factors were searched.

Results A total of 24 patients fulfilled inclusion criteria. Median age was 48 (range 22–77 years). Fourteen patients (58%) had pelvic lymph node metastases. After chemoradiation/brachytherapy, a radical hysterectomy could be performed in 18 of 24 patients (75%). Histologically complete resection was achieved in 14 (78%) of 18 patients. Complete pathological response was reported in 7 (39%) of 18. With median follow-up of 29.7 months, 10 (42%) of 24 patients experienced tumor relapse, all associated with distant failure, including one local failure. The DFS and OS rates estimated at 3 years were 55% and 63%, respectively. Lymph node metastases and tumor stage were prognostic for DFS (P = 0.016 and P = 0.022, respectively). Complete resection was associated with a lower incidence of relapses, as compared with microscopically incomplete resection (P = 0.04). A total of 12 (86%) of 14 patients with histologically complete resection were in complete remission at last follow-up. Apart from manageable acute hematological toxicities, most treatment complications were mild to moderate.

Conclusions This series based on a multimodal management compares favorably with previously published data. Most patients could be eligible to surgery, and complete remission was achieved in 85% of those amenable to complete resection.

  • Neuroendocrine tumor
  • Cervical cancer
  • Brachytherapy
  • Hysterectomy
  • Chemotherapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.